4.7 Article

Cost-effectiveness analysis of COVID-19 screening strategy under China's dynamic zero-case policy

期刊

FRONTIERS IN PUBLIC HEALTH
卷 11, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fpubh.2023.1099116

关键词

COVID-19; cost-effectiveness; screening strategy; agent-based model; dynamic zero-case policy; China

向作者/读者索取更多资源

This study used cost-effectiveness analysis to optimize COVID-19 screening strategies under China's dynamic zero-case policy. Nine screening strategies with different screening frequencies and combinations of detection methods were designed. A stochastic agent-based model simulated the progress of the COVID-19 outbreak in two scenarios. The results showed that high-frequency screening is cost-effective and can help contain the spread of the epidemic under China's COVID-19 dynamic zero-case policy. Mass antigen testing is not cost-effective compared to mass nucleic acid testing, and using AT as a supplemental screening tool is more cost-effective when NAT capacity is insufficient or when outbreaks are spreading rapidly.
This study aims to optimize the COVID-19 screening strategies under China's dynamic zero-case policy through cost-effectiveness analysis. A total of 9 screening strategies with different screening frequencies and combinations of detection methods were designed. A stochastic agent-based model was used to simulate the progress of the COVID-19 outbreak in scenario I (close contacts were promptly quarantined) and scenario II (close contacts were not promptly quarantined). The primary outcomes included the number of infections, number of close contacts, number of deaths, the duration of the epidemic, and duration of movement restriction. Net monetary benefit (NMB) and the incremental cost-benefit ratio were used to compare the cost-effectiveness of different screening strategies. The results indicated that under China's COVID-19 dynamic zero-case policy, high-frequency screening can help contain the spread of the epidemic, reduce the size and burden of the epidemic, and is cost-effective. Mass antigen testing is not cost-effective compared with mass nucleic acid testing in the same screening frequency. It would be more cost-effective to use AT as a supplemental screening tool when NAT capacity is insufficient or when outbreaks are spreading very rapidly.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据